Enhanced steatosis by nuclear receptor ligands: A study in cultured human hepatocytes and hepatoma cells with a characterized nuclear receptor expression profile

Chemico-Biological Interactions

Volumn 184, Issue 3, 2010, Pages 376-387

  Moya, Marta ^a   Jose Gomez Lechon M ^a,b   Castell, José V ^a,b,c   Jover, Ramiro ^a,b,c  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Cultured human hepatocytes; Fatty acids; HepG2; NAFLD; Nuclear receptor ligands; Steatosis

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 1; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; CONSTITUTIVE ANDROSTANE RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FARNESOID X RECEPTOR; FATTY ACID SYNTHASE; GLUCOCORTICOID RECEPTOR; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; LIVER RECEPTOR HOMOLOG 1; LIVER X RECEPTOR ALPHA; MESSENGER RNA; PAXILLINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PORPHOBILINOGEN DEAMINASE; PREGNANE X RECEPTOR; PROTEIN TYROSINE PHOSPHATASE SHP; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; THYROID HORMONE RECEPTOR ALPHA; THYROID HORMONE RECEPTOR BETA; TRANSFERRIN BINDING PROTEIN; VITAMIN D RECEPTOR;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ANALYSIS; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LIPID STORAGE; LIPOGENESIS; LIVER CELL; MALE; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; POLYMERASE CHAIN REACTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; STEATOSIS;

ANDROSTENOLS; BICYCLO COMPOUNDS; CALCIFEDIOL; CELLS, CULTURED; CHOLESTEROL; FARNESOL; FATTY LIVER; HEP G2 CELLS; HEPATOCYTES; HUMANS; INDOLES; LIGANDS; PHLOROGLUCINOL; PPAR GAMMA; PREGNENEDIONES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TERPENES; VITAMIN A;

EID: 77949916811     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.01.008     Document Type: Article

References (73)

1. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., Ferrell L.D., Liu Y.C., Torbenson M.S., Unalp-Arida A., Yeh M., McCullough A.J., Sanyal A.J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
2. Marchesini G., Bugianesi E., Forlani G., Cerrelli F., Lenzi M., Manini R., Natale S., Vanni E., Villanova N., Melchionda N., Rizzetto M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
3. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346(16):1221-1231.
4. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
5. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
6. Bugianesi E., Leone N., Vanni E., Marchesini G., Brunello F., Carucci P., Musso A., De Paolis P., Capussotti L., Salizzoni M., Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
7. Wieckowska A., McCullough A.J., Feldstein A.E. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007, 46:582-589.
8. Tamura S., Shimomura I. Contribution of adipose tissue and de novo lipogenesis to nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1139-1142.
9. George J., Liddle C. Nonalcoholic fatty liver disease: pathogenesis and potential for nuclear receptors as therapeutic targets. Mol. Pharm. 2008, 5:49-59.
10. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 2005, 115:1343-1351.
11. Farrell G.C. Drugs and steatohepatitis. Semin. Liver Dis. 2002, 22(2):185-194.
12. Jump D.B., Botolin D., Wang Y., Xu J., Christian B., Demeure O. Fatty acid regulation of hepatic gene transcription. J. Nutr. 2005, 135:2503-2506.
13. Anderson N., Borlak J. Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 2008, 60:311-357.
14. Gaemers I.C., Groen A.K. New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr. Opin. Lipidol. 2006, 17:268-273.
15. Grimaldi P.A. Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives. Cell. Mol. Life Sci. 2007, 64:2459-2464.
16. Kallwitz E.R., McLachlan A., Cotler S.J. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J. Gastroenterol. 2008, 14:22-28.
17. Kalaany N.Y., Mangelsdorf D.J. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 2006, 68:159-191.
18. Konno Y., Negishi M., Kodama S. The roles of nuclear receptors CAR and PXR in hepatic energy metabolism. Drug Metab. Pharmacokinet. 2008, 23:8-13.
19. Moreau A., Vilarem M.J., Maurel P., Pascussi J.M. Xenoreceptors CAR and PXR activation and consequences on lipid metabolism, glucose homeostasis, and inflammatory response. Mol. Pharm. 2008, 5:35-41.
20. Beaven S.W., Tontonoz P. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 2006, 57:313-329.
21. Chawla A., Repa J.J., Evans R.M., Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
22. Hummasti S., Tontonoz P. Adopting new orphans into the family of metabolic regulators. Mol. Endocrinol. 2008, 22:1743-1753.
23. Shulman A.I., Mangelsdorf D.J. Retinoid x receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 2005, 353:604-615.
24. Berkenstam A., Gustafsson J.A. Nuclear receptors and their relevance to diseases related to lipid metabolism. Curr. Opin. Pharmacol. 2005, 5:171-176.
25. Anstee Q.M., Goldin R.D. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 2006, 87:1-16.
26. Gomez-Lechon M.J., Donato M.T., Martinez-Romero A., Jimenez N., Castell J.V., O'Connor J.E. A human hepatocellular in vitro model to investigate steatosis. Chem. Biol. Interact. 2007, 165:106-116.
27. Castell J.V., Hernandez D., Gomez-Foix A.M., Guillen I., Donato T., Gomez-Lechon M.J. Adenovirus-mediated gene transfer into human hepatocytes: analysis of the biochemical functionality of transduced cells. Gene Ther. 1997, 4:455-464.
28. Jover R., Bort R., Gomez-Lechon M.J., Castell J.V. Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology 2001, 33:668-675.
29. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3. [RESEARCH0034].
30. Gomez-Lechon M.J., Donato M.T., Castell J.V., Jover R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr. Drug Metab. 2003, 4:292-312.
31. Castell J.V., Jover R., Martinez-Jimenez C.P., Gomez-Lechon M.J. Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. Expert Opin. Drug Metab. Toxicol. 2006, 2:183-212.
32. Horton J.D., Goldstein J.L., Brown M.S. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Invest. 2002, 109:1125-1131.
33. Nguyen M.C., Stewart R.B., Banerji M.A., Gordon D.H., Kral J.G. Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer. Int. J. Obes. Relat. Metab. Disord. 2001, 25:296-298.
34. Lelliott C.J., Lopez M., Curtis R.K., Parker N., Laudes M., Yeo G., Jimenez-Linan M., Grosse J., Saha A.K., Wiggins D., Hauton D., Brand M.D., O'Rahilly S., Griffin J.L., Gibbons G.F., Vidal-Puig A. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J. 2005, 19:1108-1119.
35. Gudbrandsen O.A., Rost T.H., Berge R.K. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J. Lipid. Res. 2006, 47:2223-2232.
36. Barkhem T., Carlsson B., Nilsson Y., Enmark E., Gustafsson J., Nilsson S. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 1998, 54:105-112.
37. Alvaro D., Alpini G., Onori P., Perego L., Svegliata Baroni G., Franchitto A., Baiocchi L., Glaser S.S., Le Sage G., Folli F., Gaudio E. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology 2000, 119:1681-1691.
38. Wong J., Quinn C.M., Gelissen I.C., Brown A.J. Endogenous 24(S),25-epoxycholesterol fine-tunes acute control of cellular cholesterol homeostasis. J. Biol. Chem. 2008, 283:700-707.
39. Janowski B.A., Grogan M.J., Jones S.A., Wisely G.B., Kliewer S.A., Corey E.J., Mangelsdorf D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:266-271.
40. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 2000, 14:2831-2838.
41. Grefhorst A., Elzinga B.M., Voshol P.J., Plosch T., Kok T., Bloks V.W., van der Sluijs F.H., Havekes L.M., Romijn J.A., Verkade H.J., Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 2002, 277:34182-34190.
42. Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.M., Hammer R.E., Mangelsdorf D.J. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell 1998, 93:693-704.
43. Zhou J., Febbraio M., Wada T., Zhai Y., Kuruba R., He J., Lee J.H., Khadem S., Ren S., Li S., Silverstein R.L., Xie W. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology 2008, 134:556-567.
44. Moore L.B., Goodwin B., Jones S.A., Wisely G.B., Serabjit-Singh C.J., Willson T.M., Collins J.L., Kliewer S.A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:7500-7502.
45. Cui Y., Ang C.Y., Beger R.D., Heinze T.M., Hu L., Leakey J. In vitro metabolism of hyperforin in rat liver microsomal systems. Drug Metab. Dispos. 2004, 32:28-34.
46. Nakamura K., Moore R., Negishi M., Sueyoshi T. Nuclear pregnane X receptor cross-talk with FoxA2 to mediate drug-induced regulation of lipid metabolism in fasting mouse liver. J. Biol. Chem. 2007, 282:9768-9776.
47. Zhou J., Zhai Y., Mu Y., Gong H., Uppal H., Toma D., Ren S., Evans R.M., Xie W. A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway. J. Biol. Chem. 2006, 281:15013-15020.
48. Moreau A., Teruel C., Beylot M., Albalea V., Tamasi V., Umbdenstock T., Parmentier Y., Sa-Cunha A., Suc B., Fabre J.M., Navarro F., Ramos J., Meyer U., Maurel P., Vilarem M.J., Pascussi J.M. A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 2009, 49:2068-2079.
49. Maglich J.M., Lobe D.C., Moore J.T. The nuclear receptor CAR (NR1I3) regulates serum triglyceride levels under conditions of metabolic stress. J. Lipid Res. 2009, 50:439-445.
50. Osabe M., Sugatani J., Fukuyama T., Ikushiro S., Ikari A., Miwa M. Expression of hepatic UDP-glucuronosyltransferase 1A1 and 1A6 correlated with increased expression of the nuclear constitutive androstane receptor and peroxisome proliferator-activated receptor alpha in male rats fed a high-fat and high-sucrose diet. Drug Metab. Dispos. 2008, 36:294-302.
51. Yamazaki Y., Kakizaki S., Horiguchi N., Sohara N., Sato K., Takagi H., Mori M., Negishi M. The role of the nuclear receptor constitutive androstane receptor in the pathogenesis of non-alcoholic steatohepatitis. Gut 2007, 56:565-574.
52. Baskin-Bey E.S., Anan A., Isomoto H., Bronk S.F., Gores G.J. Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse. World J. Gastroenterol. 2007, 13:5635-5641.
53. Soprano D.R., Qin P., Soprano K.J. Retinoic acid receptors and cancers. Annu. Rev. Nutr. 2004, 24:201-221.
54. Blomhoff R., Blomhoff H.K. Overview of retinoid metabolism and function. J. Neurobiol. 2006, 66:606-630.
55. Repa J.J., Hanson K.K., Clagett-Dame M. All-trans-retinol is a ligand for the retinoic acid receptors. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:7293-7297.
56. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., Noonan D.J., Burka L.T., McMorris T., Lamph W.W., Evans R.M., Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81:687-693.
57. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., Hull M.V., Lustig K.D., Mangelsdorf D.J., Shan B. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
58. Urizar N.L., Liverman A.B., Dodds D.T., Silva F.V., Ordentlich P., Yan Y., Gonzalez F.J., Heyman R.A., Mangelsdorf D.J., Moore D.D. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002, 296:1703-1706.
59. Takahashi N., Kawada T., Goto T., Yamamoto T., Taimatsu A., Matsui N., Kimura K., Saito M., Hosokawa M., Miyashita K., Fushiki T. Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes. FEBS Lett. 2002, 514:315-322.
60. Brobst D.E., Ding X., Creech K.L., Goodwin B., Kelley B., Staudinger J.L. Guggulsterone activates multiple nuclear receptors and induces CYP3A gene expression through the pregnane X receptor. J. Pharmacol. Exp. Ther. 2004, 310:528-535.
61. Urizar N.L., Moore D.D. GUGULIPID: a natural cholesterol-lowering agent. Annu. Rev. Nutr. 2003, 23:303-313.
62. Duncan R.E., Archer M.C. Farnesol decreases serum triglycerides in rats: identification of mechanisms including up-regulation of PPARalpha and down-regulation of fatty acid synthase in hepatocytes. Lipids 2008, 43:619-627.
63. Gervois P., Torra I.P., Chinetti G., Grotzinger T., Dubois G., Fruchart J.C., Fruchart-Najib J., Leitersdorf E., Staels B. A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. Mol. Endocrinol. 1999, 13:1535-1549.
64. Zhu Y., Qi C., Korenberg J.R., Chen X.N., Noya D., Rao M.S., Reddy J.K. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7921-7925.
65. Elbrecht A., Chen Y., Cullinan C.A., Hayes N., Leibowitz M., Moller D.E., Berger J. Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem. Biophys. Res. Commun. 1996, 224:431-437.
66. Werman A., Hollenberg A., Solanes G., Bjorbaek C., Vidal-Puig A.J., Flier J.S. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J. Biol. Chem. 1997, 272:20230-20235.
67. Mukherjee R., Jow L., Croston G.E., Paterniti J.R. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. 1997, 272:8071-8076.
68. Zirlik A., Leugers A., Lohrmann J., Ernst S., Sobel B.E., Bode C., Nordt T.K. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb. Haemost. 2004, 91:674-682.
69. Masubuchi Y., Kano S., Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology 2006, 222:233-239.
70. Guo L., Zhang L., Sun Y., Muskhelishvili L., Blann E., Dial S., Shi L., Schroth G., Dragan Y.P. Differences in hepatotoxicity and gene expression profiles by anti-diabetic PPAR gamma agonists on rat primary hepatocytes and human HepG2 cells. Mol. Divers. 2006, 10:349-360.
71. Schild R.L., Schaiff W.T., Carlson M.G., Cronbach E.J., Nelson D.M., Sadovsky Y. The activity of PPAR gamma in primary human trophoblasts is enhanced by oxidized lipids. J. Clin. Endocrinol. Metab. 2002, 87:1105-1110.
72. Gavrilova O., Haluzik M., Matsusue K., Cutson J.J., Johnson L., Dietz K.R., Nicol C.J., Vinson C., Gonzalez F.J., Reitman M.L. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 2003, 278:34268-34276.
73. Yu S., Matsusue K., Kashireddy P., Cao W.Q., Yeldandi V., Yeldandi A.V., Rao M.S., Gonzalez F.J., Reddy J.K. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem. 2003, 278:498-505.